What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2022-03-16 compared with 2021-03-23 · 321 added, 279 removed, 38 unchanged (94% of the section changed)

Company’s business is subject to numerous risks, including but not limited to those set forth below.

The Company’s

operations and performance could also be subject to risks that do not exist as of the date of this report but emerge thereafter

as well as risks that the Company does not currently deem material.

The Company’s operations

and performance could also be subject to risks that do not exist as of the date of this report but emerge thereafter as well as risks

that the Company does not currently deem material.

Related to the Company’s Operations

business, operations, financial condition, and liquidity have been and may continue to be affected by the outbreak of COVID-19.

March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic.

The spread of COVID-19 in

the United States and the measures to contain it—including business shutdowns, indoor capacity restrictions, social distancing,

and diminished travel—have negatively impacted the economy and created significant volatility and disruption in financial

Business shutdowns in certain states in response to stay-at-home orders and related measures had temporarily eliminated

access to our dispensaries by certain customers, principally non-medical use customers, impacting sales during this restricted

Further, the volatility in the financial markets and investor uncertainty has delayed our financing efforts and the implementation

of our Consolidation Plan.

As a result, our business, operations, financial condition, and liquidity have been and may

continue to be impacted.

Further, the disruption to the global economy and to our business, along with the decline in our stock

price, may also negatively impact the future carrying values of certain assets, including inventories, accounts receivables, intangibles,

and goodwill.

Company’s business, operations, financial

condition, and liquidity have been and may continue to be affected by the outbreak of COVID-19.

In March 2020, the World Health Organization declared

the outbreak of COVID-19 a global pandemic.

The spread of COVID-19 in the United States and the measures to contain it—including

business shutdowns, indoor capacity restrictions, social distancing, and diminished travel—have negatively impacted the economy

and created significant volatility and disruption in financial markets.

Business shutdowns in certain states in response to stay-at-home

orders and related measures had temporarily eliminated access to the Company’s dispensaries by certain customers, principally

non-medical use customers, impacting sales during this restricted period.

Further, the volatility in the financial markets and investor

uncertainty has delayed the implementation of the Company’s Consolidation Plan.

As a result, the Company’s

business, operations, financial condition, and liquidity have been and may continue to be impacted.

Further, the disruption to the global

economy and to the Company’s business, along with the decline in its stock price, may also negatively impact the

future carrying values of certain assets, including inventories, accounts receivables, intangibles, and goodwill.

remains illegal under federal law.

Marijuana remains illegal under federal law.

Cannabis remains illegal under federal law.

It is a Schedule I controlled substance.

Even in those jurisdictions in which the use of medical marijuana has been legalized

at the state level, its prescription is a violation of federal law.

The United States Supreme Court has ruled that it is the federal

government that has the right to regulate and criminalize cannabis, even for medical purposes.

Therefore, federal law criminalizing

the use of marijuana trumps state laws that legalize its use for even medicinal purposes.

At present the states are standing tall

against the federal government, maintaining existing laws and passing new ones in this area.

States continue to exert this freedom,

with more states considering legalization.

However, we continually face election cycles, and a new administration or the United

States Congress could introduce a less favorable policy.

A change in the federal attitude towards enforcement could cripple the

There is currently broad support for changes in the federal law for improved banking, investing, and the potential

legalization of cannabis.

However, there is no certainty what will get changed or when.

The medical and recreational

marijuana industries are our primary markets, and if these industries were to be unable to operate, we would

lose our potential clients and licenses, which would have a significantly negative impact on our business, operations,

and financial condition.

growth is dependent on additional states legalizing marijuana.

development of the marijuana market is dependent upon continued legislative authorization of marijuana at the state level for

medical and adult recreational use.

Any number of factors could slow or halt the progress.

Further, progress, while encouraging,

is not assured and the process normally encounters set-backs before achieving success.

While there may be ample public support

for legislative proposal, key support must be created in the legislative committee or a bill may never advance to a vote.

factors impact the legislative process.

Any one of these factors could slow or halt the progress and adoption of marijuana for

medical and/or recreational purposes, which would limit the market for our products and negatively impact our ability to grow

into other states.

will be difficult for you to evaluate us based on our past performance because we are transitioning our business in a new emerging

industry with a limited operating history.

have been actively engaged in the marijuana related business for a relatively short period of time and, accordingly, have only

limited financial results on which you can evaluate our company and operations.

In addition, the components of our revenue and

costs are changing as we move away from a fee-based-only business to seed-to-sale operations.

We are subject to, and must be successful

in addressing, the risks typically encountered by companies operating in the rapidly evolving cannabis marketplace, including

those risks relating to:

Even in those jurisdictions in which the use of medical cannabis has been legalized at

the state level, its prescription is a violation of federal law.

The United States Supreme Court has ruled that it is the federal government

that has the right to regulate and criminalize cannabis, even for medical purposes.

Therefore, federal law criminalizing the use of cannabis

trumps state laws that legalize its use for even medicinal purposes.

At present the states are standing tall against the federal

government, maintaining existing laws and passing new ones in this area.

States continue to exert this freedom, with more states considering

legalization.

However, the Company continually faces election cycles, and a new administration or the United States Congress

could introduce a less favorable policy.

A change in the federal attitude towards enforcement could cripple the industry.

There is currently

broad support for changes in the federal law for improved banking, investing, and the potential legalization of cannabis.

However, there

is no certainty what will get changed or when.

The medical and recreational cannabis industries are the Company’s

primary markets, and if these industries were to be unable to operate, the Company would lose its potential clients and licenses,

which would have a significantly negative impact on the Company’s business, operations, and financial condition.

growth is dependent on additional states legalizing cannabis.

Continued development of the cannabis market

is dependent upon continued legislative authorization of cannabis at the state level for medical and adult recreational use.

number of factors could slow or halt the progress.

Further, progress, while encouraging, is not assured and the process normally encounters

set-backs before achieving success.

While there may be ample public support for legislative proposal, key support must be created in

the legislative committee, or a bill may never advance to a vote.

Numerous factors impact the legislative process.

these factors could slow or halt the progress and adoption of cannabis for medical and/or recreational purposes, which would limit

the market for the Company’s products and negatively impact its ability to grow into other states.

Company’s consolidation plan and growth strategy is subject to regulatory hurdles.

Company’s strategy to expand its footprint into additional legal cannabis states through new applications and acquisitions of existing

cannabis businesses is subject, in each respective jurisdiction, to the approval of a new license application or license transfer application.

Such approvals are subject to numerous delays and uncertainties based upon administrative and legislative changes in what are typically,

in light of the recent cannabis legalization status in most jurisdictions, new and untested rules and regulations.

There is little interpretative

guidance on how states will apply their respective licensing regulations and limited control over when an application will be acted upon.

As a result, there is no assurance that the Company’s expansion plan will not be frustrated by regulatory delays, and no assurance

that any license application or transfer application will be approved.

It will be difficult to evaluate the

Company based on its past performance because it is transitioning its business into that of an owner of cannabis licenses and operator

of cannabis operations.

The Company has been actively engaged in the cannabis industry as an MSO for a relatively short period of time and, accordingly, has only limited financial results on which it can be evaluated.

In addition, the components of the Company’s revenue and costs are changing as it continues to move

away from a fee-based-only business to a multi-state seed-to-sale operation.

The Company is subject to, and must be successful in addressing,

the risks typically encountered by companies operating in the rapidly evolving cannabis marketplace, including those risks relating to:

failure to develop brand name recognition and reputation;

failure to achieve market acceptance of our services;

slowdown in general consumer acceptance of legalized marijuana;

inability to grow and adapt our business to evolving consumer demand.

failure to achieve market acceptance of the Company’s services;

slowdown in general consumer acceptance of legalized cannabis;

inability to grow and adapt the Company’s business to evolving consumer demand.

medical cannabis industry faces strong opposition from traditional medicines.

is believed by many that existing, entrenched, well-funded, businesses may have a strong economic opposition to the medical marijuana

industry as currently formed.

For example, we believe that the pharmaceutical industry does not want to cede control of any compound

that could become a strong selling drug.

Specifically, medical marijuana will likely adversely impact the existing market for

Marinol, the current “marijuana pill” sold by mainstream pharmaceutical companies.

Further, the medical marijuana

industry could face a material threat from the pharmaceutical industry should marijuana displace other drugs or simply encroach

upon the pharmaceutical industry’s market share for compounds such as marijuana and its component parts.

The pharmaceutical

industry is well funded with a strong and experienced lobby that eclipses the funding of the medical marijuana movement.

the pharmaceutical industry makes in halting or rolling back the medical marijuana movement could have a detrimental impact on

the market for our products and thus on our business, operations and financial condition.

clients may have difficulty accessing the service of banks, which may make it difficult for them to purchase our products and

discussed above, the use of marijuana is illegal under federal law.

Therefore, there are banks that will not accept for deposit

funds from sale of cannabis and may choose not to do business with our clients.

While there is pending legislation in the United

States Senate that will allow banks to transact business with state-authorized medical marijuana businesses, there can be no assurance

his legislation will be successful, that banks will decide to do business with medical marijuana retailers, or that in the absence

of legislation state and federal banking regulators will not create issues on banks handling funds generated from an activity

that is illegal under federal law.

Notwithstanding, the Company has been able to secure state-chartered banks that are in compliance

with federal law and provide certain banking services to companies in the cannabis industry.

The inability of potential clients

in our target market to open accounts and otherwise use the service of banks may make it difficult for them to purchase our products

It is believed by many that existing, entrenched,

well-funded, businesses may have a strong economic opposition to the medical cannabis industry as currently formed.

the Company believes that the pharmaceutical industry does not want to cede control of any compound that could become a strong

selling drug.

Specifically, medical cannabis will likely adversely impact the existing market for Marinol, the current “cannabis

pill” sold by mainstream pharmaceutical companies.

Further, the medical cannabis industry could face a material threat

from the pharmaceutical industry should cannabis displace other drugs or simply encroach upon the pharmaceutical industry’s

market share for compounds such as cannabis and its component parts.

The pharmaceutical industry is well funded with a strong

and experienced lobby that eclipses the funding of the medical cannabis movement.

Any inroads the pharmaceutical industry makes

in halting or rolling back the medical cannabis movement could have a detrimental impact on the market for the Company’s

products and thus on its business, operations and financial condition.

The Company’s clients may

have difficulty accessing the service of banks, which may make it difficult for such clients to purchase the Company’s

products and services.

As discussed above, the use of cannabis is

illegal under federal law.

Therefore, there are banks that will not accept for deposit funds from sale of cannabis and may choose not

to do business with the Company’s clients.

While there is pending legislation in the United States Senate that will allow

banks to transact business with state-authorized medical cannabis businesses, there can be no assurance his legislation will be

successful, that banks will decide to do business with medical cannabis retailers, or that in the absence of legislation state

and federal banking regulators will not create issues on banks handling funds generated from an activity that is illegal under federal

Notwithstanding, the Company has been able to secure state-chartered banks that are in compliance with federal law and provide certain

banking services to companies in the cannabis industry.

The inability of potential clients in the Company’s target market

to open accounts and otherwise use the service of banks may make it difficult for them to purchase the Company’s products

and services.

may not be able to economically comply with any new government regulation that may be adopted with respect to the cannabis industry.

legislation or regulation, or the application of existing laws and regulations to the medical and consumer cannabis industries

could add additional costs and risks to doing business.

We are subject to regulations applicable to businesses generally and laws

or regulations directly applicable to communications over the Internet and access to e-commerce.

Although there are currently

few laws and regulations regulating the cannabis products, it is reasonable to assume that as cannabis use becomes more mainstream

that the FDA and or other federal, state and local governmental agencies will impose regulations covering the cultivation, purity,

privacy, quality control, security and many other aspects of the industry, all of which will likely raise the cost of compliance

thereby reducing profits or even making it more difficult to continue operations, either of which scenarios, if they occur, could

have a negative impact on our business and operations.

relatively small size and limited resources may restrict our ability to manage any growth we may experience.

of our business may place a significant strain on our management systems and resources and may require us to implement new operating

The Company may not be able to economically

comply with any new government regulation that may be adopted with respect to the cannabis industry.

New legislation or regulation, or the application

of existing laws and regulations to the medical and consumer cannabis industries could add additional costs and risks to doing business.

the Company is subject to regulations applicable to businesses generally and laws or regulations directly applicable to communications

over the Internet and access to e-commerce.

Although there are currently few laws and regulations regulating the cannabis products, it

is reasonable to assume that as cannabis use becomes more mainstream that the FDA and or other federal, state and local governmental

agencies will impose regulations covering the cultivation, purity, privacy, quality control, security and many other aspects of the industry,

all of which will likely raise the cost of compliance thereby reducing profits or even making it more difficult to continue operations,

either of which scenarios, if they occur, could have a negative impact on the Company’s business and operations.

The Company’s relatively small

size and limited resources may restrict its ability to manage any growth it may experience.

Growth of the Company’s business may

place a significant strain on its management systems and resources and may require the Company to implement new operating

and financial systems, procedures and controls.

Our failure to manage our growth and expansion could adversely affect our business,

results of operations and financial condition.

Failure to implement new systems effectively or within a reasonable period of time

could adversely affect our business, results of operations and financial condition.

The Company is constantly looking to add additional

qualified talent to the management team to support its growth, but there is no assurance we will be successful in identifying

and/or hiring such people.

market may not readily accept our products.

and market acceptance for our licensed branded new cannabis-infused products are subject to a high level of uncertainty.

The successful

introduction of any new product requires a focused, efficient strategy to create awareness of and desire for the products.

example, in order to achieve market acceptance for our marijuana products we will need to gain market and patient acceptance.

Despite management’s efforts to gather data before introducing new products as a means to minimize the risk of product non-acceptance,

no assurance can be given that our efforts will be successful.

marketing strategy may be unsuccessful and is subject to change as a result of a number of factors, including changes in market

conditions (including the emergence of new market segments which in our judgment can be readily exploited through the use of our

technology), the nature of possible license and distribution arrangements and strategic alliances which may become available to

us in the future and general economic, regulatory and competitive factors.

There can be no assurance that our strategy will result

in successful product commercialization or that our efforts will result in initial or continued market acceptance for our proposed

we are unable to protect our intellectual property rights, competitors may be able to use our technology or trademarks, which

could weaken our competitive position.

rely on a combination of copyright, trademark and trade secret laws and restrictions on disclosure to protect our intellectual

property rights.

We enter into confidentiality or license agreements with our employees, consultants and customers, and control

access to and distribution of our products, and other proprietary information.

Despite our efforts to protect our proprietary

rights, unauthorized parties may attempt to copy or otherwise obtain and use our products.

we lose our key employee or fail to hire and retain other talented employees when necessary, our operations could be harmed.

success of our business is currently dependent, in large part, on the personal efforts of Messrs.

the Company’s failure to manage its growth and expansion could adversely

affect its business, results of operations and financial condition.

Failure to implement new systems effectively or within a reasonable

period of time could adversely affect the Company’s business, results of operations and financial condition.

is constantly looking to add additional qualified talent to the management team to support its growth, but there is no assurance it

will be successful in identifying and/or hiring such people.

The market may not readily accept the Company’s

Demand and market acceptance for the Company’s

licensed branded new cannabis-infused products are subject to a high level of uncertainty.

The successful introduction of any new

product requires a focused, efficient strategy to create awareness of and desire for the products.

For example, in order to achieve market

acceptance for the Company’s cannabis products it will need to gain market and patient acceptance.

management’s efforts to gather data before introducing new products as a means to minimize the risk of product non-acceptance,

no assurance can be given that the Company’s efforts will be successful.

The Company’s marketing strategy may

be unsuccessful and is subject to change as a result of a number of factors, including changes in market conditions (including the emergence

of new market segments which in the Company’s judgment can be readily exploited through the use of its technology),

the nature of possible license and distribution arrangements and strategic alliances which may become available to us in the future and

general economic, regulatory and competitive factors.

There can be no assurance that the Company’s strategy will result

in successful product commercialization or that its efforts will result in initial or continued market acceptance for its

proposed products.

If the Company is unable to protect its

intellectual property rights, competitors may be able to use the Company’s technology or trademarks, which could weaken

its competitive position.

The Company relies on a combination of copyright,

trademark, and trade secret laws and restrictions on disclosure to protect its intellectual property rights.

The Company enters

into confidentiality or license agreements with its employees, consultants and customers, and controls access to and distribution

of its products, and other proprietary information.

Despite the Company’s efforts to protect its proprietary

rights, unauthorized parties may attempt to copy or otherwise obtain and use its products.

If the Company loses its key employees

or fails to hire and retain other talented employees when necessary, its operations could be harmed.

The success of the Company’s business

is currently dependent, in large part, on the personal efforts of Messrs.

Robert Fireman, Jon R.

and Timothy Shaw, our chief executive officer, chief financial officer, and chief operating officer, respectively.

their services could have a material adverse effect on our business.

The success of our business is currently dependent, in large

part, upon our ability to hire and retain additional qualified management, marketing, technical, financial, and other personnel

if and when our growth so requires.

Competition for qualified personnel is intense and we may not be able to hire or retain such

additional qualified personnel.

Any inability to attract and retain qualified management and other personnel would have a material

adverse effect on our ability to grow our business and operations.

face competition from entities with greater resources than we have.

is potential that the Company will face intense competition from other companies, some of which can be expected to have longer

operating histories and more financial resources and experience than the Company.

Increased competition by larger and better-financed

competitors could materially and adversely affect the business, financial condition, results of operations or prospects of the

of the early stage of the industry in which the Company operates, the Company expects to face additional competition from new

To become and remain competitive, the Company will require research and development, marketing, sales and support.

Company may not have sufficient resources to maintain research and development, marketing, sales and support efforts on a competitive

basis which could materially and adversely affect the business, financial condition, results of operations or prospects of the

introduction of a recreational model for cannabis production and distribution may impact the medical marijuana market.

of this potential development may be negative for the Company, and could result in increased levels of competition in its existing

medical market and/or the entry of new competitors in the overall cannabis market in which the Company operates.

change in federal laws regarding the classification of cannabis as a controlled substance, interstate cannabis commerce, banking

for entities in the cannabis industry, or other related regulations may have a significant impact on the Company’s business.

of clinical research, if unfavorable, could have a negative impact on the industries in which we operate and consequently on our

business model.

in Canada, the United States and internationally regarding the medical benefits, viability, safety, efficacy, dosing and social

acceptance of cannabis or isolated cannabinoids (such as CBD and THC) remains in early stages.

There have been relatively few

clinical trials on the benefits of cannabis or isolated cannabinoids (such as CBD and THC).

Although the Company believes that

the articles, reports and studies support its beliefs regarding the medical benefits, viability, safety, efficacy, dosing and

social acceptance of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns

regarding, and perceptions relating to, cannabis.

Future research studies and clinical trials may reach negative conclusions regarding

the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to cannabis,

which could have a material adverse effect on the demand for the Company’s products with the potential to lead to a material

adverse effect on the Company’s business, financial condition, results of operations or prospects.

face the prospect of claims of product liability if anyone is harmed by our products.

Company’s products will be produced for sale directly to end consumers, and therefore there is an inherent risk of exposure

to product liability claims, regulatory action and litigation if the products are alleged to have caused loss or injury.

the production and sale of the Company’s products involves the risk of injury to end users due to tampering by unauthorized

third parties or product contamination.

Previously unknown adverse reactions resulting from human or animal consumption of the

Company’s products alone or in combination with other medications or substances could occur.

The Company may be subject

to various product liability claims, including, among others, that its products caused injury or illness, include inadequate instructions

for use or include inadequate warnings concerning possible side effects or interactions with other substances.

While the Company

has product liability insurance coverage in place and works with third party providers to ensure they do as well, a product liability

claim or regulatory action against the Company could exceed our insurance coverage, and could adversely affect the Company’s

reputation and have a material adverse effect on its business and operational results.

are subject to compliance with environmental regulations which can be onerous and costly.

Company’s operations are subject to environmental regulation in the various jurisdictions in which it operates.

These regulations

mandate, among other things, the maintenance of air and water quality standards and land reclamation.

They also set forth limitations

on the generation, transportation, storage and disposal of solid and hazardous waste.

Environmental legislation is evolving in

a manner which will require stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent

environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors

and employees.

There is no assurance that future changes in environmental regulation, if any, will not adversely affect the Company’s

environmental approvals and permits are currently, and may in the future, be required in connection with the Company’s operations.

To the extent such approvals are required and not obtained, the Company may be curtailed or prohibited from implementing its proposed

business activities or from proceeding with the development of its operations as currently proposed.

to comply with applicable environmental laws, regulations and permitting requirements may result in enforcement actions thereunder,

including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective

measures requiring capital expenditures, installation of additional equipment, or remedial actions.

The Company may be required

to compensate those suffering loss or damage due to its operations and may have civil or criminal fines or penalties imposed for

violations of applicable laws or regulations which could have a material adverse effect on its business and operational results.

are subject to potential risks related to, and arising from, acquiring companies.

Company is in the process of acquiring several companies and intends to acquire other companies in the future.

There are risks

inherent in any such acquisition.

Specifically, there could be unknown or undisclosed risks or liabilities of such companies for

which the Company is not sufficiently indemnified.

Any such unknown or undisclosed risks or liabilities could materially and adversely

affect the Company’s financial performance and results of operations.

The Company could encounter additional transaction

and integration related costs or other factors such as the failure to realize all of the benefits from such acquisitions.

of these factors could cause dilution to the Company’s earnings per share or decrease or delay the anticipated accretive

effect of the acquisition and cause a decrease in the market price of the Company’s securities.

The Company may not be able

to successfully integrate and combine the operations, personnel and technology infrastructure of any such acquired company with

its existing operations.

If integration is not managed successfully by the Company’s management, the Company may experience

interruptions in its business activities, deterioration in its employee and customer relationships, increased costs of integration

and harm to its reputation, all of which could have a material adverse effect on the Company’s business, financial condition

and results of operations.

Levine, and Timothy Shaw, the Company’s

chief executive officer, chief financial officer, and chief operating officer, respectively.

The loss of their services could have

a material adverse effect on the Company’s business.

The success of the Company’s business is currently dependent,

in large part, upon its ability to hire and retain additional qualified management, marketing, technical, financial, and other personnel

if and when its growth so requires.

Competition for qualified personnel is intense and the Company may not be able to hire

or retain such additional qualified personnel.

Any inability to attract and retain qualified management and other personnel would have

a material adverse effect on the Company’s ability to grow its business and operations.

The Company faces competition from

entities with greater resources.

There is potential that the Company will face intense

competition from other companies, some of which can be expected to have longer operating histories and more financial resources and experience

than the Company.

Increased competition by larger and better-financed competitors could materially and adversely affect the business,

financial condition, results of operations or prospects of the Company.

Because of the early stage of the industry in which

the Company operates, the Company expects to face additional competition from new entrants.

To become and remain competitive, the Company

will require research and development, marketing, sales and support.

The Company may not have sufficient resources to maintain research

and development, marketing, sales and support efforts on a competitive basis which could materially and adversely affect the business,

financial condition, results of operations or prospects of the Company.

The introduction of a recreational model for cannabis

production and distribution may impact the medical cannabis market.

The impact of this potential development may be negative for

the Company, and could result in increased levels of competition in its existing medical market and/or the entry of new competitors in

the overall cannabis market in which the Company operates.

A change in federal laws regarding the classification

of cannabis as a controlled substance, interstate cannabis commerce, banking for entities in the cannabis industry, or other related regulations

may have a significant impact on the Company’s business.

Results of clinical research, if unfavorable,

could have a negative impact on the industries in which the Company operates and consequently on its business model.

Research in Canada, the United States and internationally

regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis or isolated cannabinoids (such as

CBD and THC) remains in early stages.

There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids

(such as CBD and THC).

Although the Company believes that the articles, reports and studies support its beliefs regarding the medical

benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, future research and clinical trials may prove such statements

to be incorrect, or could raise concerns regarding, and perceptions relating to, cannabis.

Future research studies and clinical trials

may reach negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and

perceptions related to cannabis, which could have a material adverse effect on the demand for the Company’s products with the potential

to lead to a material adverse effect on the Company’s business, financial condition, results of operations or prospects.

The Company faces the prospect of

claims of product liability if anyone is harmed by its products.

The Company’s products will be produced for

sale directly to end consumers, and therefore there is an inherent risk of exposure to product liability claims, regulatory action and

litigation if the products are alleged to have caused loss or injury.

In addition, the production and sale of the Company’s products

involves the risk of injury to end users due to tampering by unauthorized third parties or product contamination.

Previously unknown

adverse reactions resulting from human or animal consumption of the Company’s products alone or in combination with other medications

or substances could occur.

The Company may be subject to various product liability claims, including, among others, that its products

caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or

interactions with other substances.

While the Company has product liability insurance coverage in place and works with third party providers

to ensure they do as well, a product liability claim or regulatory action against the Company could exceed the Company’s

insurance coverage, and could adversely affect the Company’s reputation and have a material adverse effect on its business and

operational results.

The Company is subject to compliance

with environmental regulations which can be onerous and costly.

The Company’s operations are subject to environmental

regulation in the various jurisdictions in which it operates.

These regulations mandate, among other things, the maintenance of air and

water quality standards and land reclamation.

They also set forth limitations on the generation, transportation, storage and disposal

of solid and hazardous waste.

Environmental legislation is evolving in a manner which will require stricter standards and enforcement,

increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree

of responsibility for companies and their officers, directors and employees.

There is no assurance that future changes in environmental

regulation, if any, will not adversely affect the Company’s operations.

Government environmental approvals and permits are

currently, and may in the future, be required in connection with the Company’s operations.

To the extent such approvals are required

and not obtained, the Company may be curtailed or prohibited from implementing its proposed business activities or from proceeding with

the development of its operations as currently proposed.

Failure to comply with applicable environmental laws,

regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial

authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation

of additional equipment, or remedial actions.

The Company may be required to compensate those suffering loss or damage due to its operations

and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations which could have a material

adverse effect on its business and operational results.

The Company is subject to potential

risks related to, and arising from, acquiring companies.

The Company is in the process of acquiring several

companies and intends to acquire other companies in the future.

There are risks inherent in any such acquisition.

Specifically, there

could be unknown or undisclosed risks or liabilities of such companies for which the Company is not sufficiently indemnified.

unknown or undisclosed risks or liabilities could materially and adversely affect the Company’s financial performance and results

of operations.

The Company could encounter additional transaction and integration related costs or other factors such as the failure

to realize all of the benefits from such acquisitions.

All of these factors could cause dilution to the Company’s earnings per

share or decrease or delay the anticipated accretive effect of the acquisition and cause a decrease in the market price of the Company’s

The Company may not be able to successfully integrate and combine the operations, personnel and technology infrastructure

of any such acquired company with its existing operations.

If integration is not managed successfully by the Company’s management,

the Company may experience interruptions in its business activities, deterioration in its employee and customer relationships, increased

costs of integration and harm to its reputation, all of which could have a material adverse effect on the Company’s business, financial

condition and results of operations.

The Company may experience difficulties in combining corporate cultures, maintaining employee morale

and retaining key employees.

The integration of any such acquired companies may also impose substantial demands on the Management.

There is no assurance that these acquisitions will be successfully integrated in a timely or cost-efficient manner, or at all.

the event we are sued for any reason, we would face potential cost and interference with our business operations.

Company is, and may from time to time become, party to litigation in the ordinary course of business which could adversely affect

its business.

Should any litigation in which the Company is, or becomes, involved be determined against the Company, such a decision

could adversely affect the Company’s ability to continue operating.

Even if the Company is involved in litigation and wins,

litigation can redirect significant Company resources.

Litigation may also create a negative perception of the Company’s

The integration of any such acquired companies may also impose substantial demands on the Company’s

There is no assurance that these acquisitions will be successfully integrated in a timely or cost-efficient manner, or

In the event the Company is sued for

any reason, it would face potential cost and interference with its business operations.

The Company is, and may from time to time become,

party to litigation in the ordinary course of business which could adversely affect its business.

Should any litigation in which the Company

is, or becomes, involved be determined against the Company, such a decision could adversely affect the Company’s ability to continue

Even if the Company is involved in litigation and wins, litigation can redirect significant Company resources.

Litigation may

also create a negative perception of the Company’s brand.

Related to the Company’s Common Stock

issuances of the Company’s capital stock would cause dilution to its existing shareholders.

Company currently has approximately 319.1 million shares of common stock outstanding and it is authorized to issue up to 500 million

Therefore, the Company will be able to issue a substantial number of additional shares without obtaining shareholder approval.

In the event the Company elects to issue additional shares of common stock in connection with any financing, acquisition or otherwise,

current shareholders could find their holdings substantially diluted, which means they will own a smaller percentage of the Company.

In addition, the Company currently has approximately 4.9 million shares of Series B preferred stock and approximately 6.2 million

shares of Series C preferred outstanding and we it authorized to issue up to 50 million shares that the board of directors can

issue under any terms it wants and without any shareholder approval.

Company currently has approximately 335.2 million shares of common stock outstanding and it is authorized to issue up to 700

million shares.

Therefore, the Company will be able to issue a substantial number of additional shares without obtaining shareholder

In the event the Company elects to issue additional shares of common stock in connection with any financing, acquisition or

otherwise, current shareholders could find their holdings substantially diluted, which means they will own a smaller percentage of the

In addition, the Company currently has outstanding approximately 4.9 million shares of Series B preferred stock (which

convert on a one-for-one basis into shares of common stock) and approximately 6.2 million shares of Series C preferred stock (which

convert on a five-for-one basis into shares of common stock).

The Company’s board of directors is authorized to issue up to

a total of 50 million shares of preferred stock (including the previously issued shares) with terms it designates without

any further shareholder approval.

exercise or conversion of outstanding warrants and options into common stock will dilute the percentage ownership of the Company’s

other shareholders.

The sale of such common stock or other common stock in the open market could adversely affect the market price

of the Company’s common stock.

of December 31, 2020, there were approximately 26.7 million of potentially dilutive securities in the form of outstanding

options and warrants.

Also on such date, there was $1.3 million of outstanding convertible debentures payable and $350,000 of

outstanding convertible promissory notes that were potentially dilutive, whose conversion into common stock is based on a discount

to the market value of common stock on or about the future conversion date.

More convertible securities will likely be granted

in the future to the Company’s officers, directors, employees or consultants and as part of future financings.

of outstanding stock options and warrants and conversion of notes and debentures will dilute the percentage ownership of the Company’s

other shareholders.

Sales, or the expectation of sales, of a substantial number of shares of the Company’s common stock

in the private or public markets could adversely affect the prevailing market price of the Company’s common stock.

The sale of such common stock or other common stock in the open market could adversely affect the market price of

the Company’s common stock.

of December 31, 2021, there were potentially dilutive securities convertible into shares of common stock comprised of stock

options, convertible into 39,821,671 shares, warrants, convertible into 26,351,571 shares, Series B preferred stock, convertible into

4,908,333 shares, Series C preferred stock, convertible into 31,081,080, and promissory notes, convertible into 1,142,857 shares.

More convertible securities will likely be granted in the future to the Company’s officers, directors, employees or consultants

and as part of future financings.

The exercise of outstanding stock options and warrants and conversion of notes and debentures will

dilute the percentage ownership of the Company’s other shareholders.

Sales, or the expectation of sales, of a substantial number

of shares of the Company’s common stock in the private or public markets could adversely affect the prevailing market price of

the Company’s common stock.

Volatility of Common Share Price

market price of the Company’s common stock could be subject to significant fluctuations.

Some of the factors that may cause

the market price of the common stock to fluctuate include:

public’s reaction to the Company’s press releases, announcements and filings with regulatory authorities and those

of its competitors;

Some of the factors that may cause the

market price of the common stock to fluctuate include:

public’s reaction to the Company’s press releases, announcements and filings with regulatory authorities and those of

its competitors;

in broader stock market prices and volumes;

4 unchanged sentences

in the regulatory landscape applicable to the Company, the dietary supplement and/or the cannabis and hemp industries;

reports, publications or public statements relating to, or public perceptions of, the regulatory landscape applicable to the

Company, the cannabis or the hemp industry, whether correct or not;

reports, publications or public statements relating to, or public perceptions of, the regulatory landscape applicable to the Company,

the cannabis or the hemp industry, whether correct or not;

announcements

by the Company or its competitors of strategic alliances, significant contracts, new technologies, acquisitions, commercial

relationships, joint ventures or capital commitments;

by the Company or its competitors of strategic alliances, significant contracts, new technologies, acquisitions, commercial relationships,

joint ventures or capital commitments;

in the Company’s quarterly results of operations or cash flows or those of other comparable companies;

8 unchanged sentences

other risk factors described in this section or other sections of this 10-K.

realization of any of these risks and other factors beyond the Company’s control could cause the market price of the common

stock to decline significantly.

realization of any of these risks and other factors beyond the Company’s control could cause the market price of the common stock

to decline significantly.

addition, broad market and industry factors may harm the market price of the Company’s common stock.

Hence, the price of

the common stock could fluctuate based upon factors that have little or nothing to do with the Company, and these fluctuations

could materially reduce the price of the common stock regardless of the Company’s operating performance.

In the past, following

a significant decline in the market price of a company’s securities, there have been instances of securities class action

litigation having been instituted against that company.

If the Company were involved in any similar litigation, it could incur

substantial costs, Management’s attention and resources could be diverted and it could harm the Company’s business,

operating results and financial condition.

the event the Company requires additional financing and access to capital, covenants and restrictions in existing agreements may

limit the Company’s options.

of the Company’s existing financing agreements contain covenants that restrict its ability to incur additional debt, pay

dividends or redeem shares of its stock.

If the Company seeks to raise additional capital or financing, there can be no assurance

that such capital or additional financing will be available on terms that comply with existing covenants and are satisfactory

to the Company.

Hence, the price of the common

stock could fluctuate based upon factors that have little or nothing to do with the Company, and these fluctuations could materially

reduce the price of the common stock regardless of the Company’s operating performance.

In the past, following a significant decline

in the market price of a company’s securities, there have been instances of securities class action litigation having been instituted

against that company.

If the Company were involved in any similar litigation, it could incur substantial costs, Management’s attention

and resources could be diverted and it could harm the Company’s business, operating results and financial condition.

the event the Company requires additional financing and access to capital, covenants and restrictions in existing agreements may limit

the Company’s options.

of the Company’s existing financing agreements contain covenants that restrict its ability to incur additional debt, pay dividends

or redeem shares of its stock.

If the Company seeks to raise additional capital or financing, there can be no assurance that such capital

or additional financing will be available on terms that comply with existing covenants and are satisfactory to the Company.

Company has no plans to pay dividends on its common stock.

Company does not expect to declare or pay dividends on the common stock in the foreseeable future.

In addition, the payment of

cash dividends is limited by the terms of the Company’s financing agreements.

In addition, the payment of cash dividends

is limited by the terms of the Company’s financing agreements.

UNRESOLVED STAFF COMMENTS.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1A. Risk Factors